Using mathematical modeling as a resource in clinical trials

被引:8
|
作者
Afenya, EK [1 ]
机构
[1] Elmhurst Coll, Dept Math, Elmhurst, IL 60126 USA
关键词
cancer; leukemia; mathematical modeling; clinical trials;
D O I
10.3934/mbe.2005.2.421
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In light of recent clinical developments, the importance of mathematical modeling in cancer prevention and treatment is discussed. An existing model of cancer chemotherapy is reintroduced and placed within current investigative frameworks regarding approaches to treatment optimization. Areas of commonality between the model predictions and the clinical findings are investigated as a way of further validating the model predictions and also establishing mathematical foundations for the clinical studies. The model predictions are used to propose additional ways that treatment optimization could enhance the clinical processes. Arising out of these, an expanded model of cancer is proposed and a treatment model is subsequently obtained. These models predict that malignant cells in the marrow and peripheral blood exhibit the tendency to evolve toward population levels that enable them to replace normal cells in these compartments in the untreated case. In the case of dose-dense treatment along with recombinant hematopoietic growth factors, the models predict a situation in which normal and abnormal cells in the marrow and peripheral blood are obliterated by drug action, while the normal cells regain their growth capabilities through growth-factor stimulation.
引用
收藏
页码:421 / 436
页数:16
相关论文
共 50 条
  • [1] Mathematical Modeling in Immunotherapy of Cancer: Personalizing Clinical Trials
    Agur, Zvia
    Vuk-Pavlovic, Stanimir
    MOLECULAR THERAPY, 2012, 20 (01) : 1 - 2
  • [2] Can mathematical modeling remove the tarnish on old clinical trials?
    Kuntz, KM
    AMERICAN JOURNAL OF MEDICINE, 2001, 111 (02): : 155 - 156
  • [3] Mathematical Modeling in Cardiac Surgery: Helping Clinical Trials Answer the Question
    Poullis, Michael
    Poole, Robert
    SEMINARS IN CARDIOTHORACIC AND VASCULAR ANESTHESIA, 2009, 13 (02) : 81 - 86
  • [4] Bayesian modeling of resource use alongside multinational randomised clinical trials
    Gauthier, A.
    Manca, A.
    Anton, S. F.
    Dewberry, H.
    VALUE IN HEALTH, 2007, 10 (06) : A224 - A224
  • [5] Clinical Trials Referral Resource - Current clinical trials of fenretinide
    Swerdlow, RD
    Zwiebel, JA
    Gravell, AE
    Cheson, BD
    ONCOLOGY-NEW YORK, 2001, 15 (12): : 1595 - +
  • [6] Clinical trials - Referral resource
    Davis, T
    Schoenfeldt, M
    ONCOLOGY-NEW YORK, 2004, 18 (01): : 62 - +
  • [7] Clinical trials - Referral resource
    Murgo, A
    Wood, KF
    Gravell, AE
    Cheson, BD
    ONCOLOGY-NEW YORK, 2001, 15 (07): : 881 - 881
  • [8] Clinical trials referral resource
    Kaplan, RS
    Smiley, JK
    Cheson, BD
    ONCOLOGY-NEW YORK, 1999, 13 (04): : 532 - 532
  • [9] Clinical Trials Referral Resource
    Abrams, JS
    Schoenfeldt, M
    ONCOLOGY-NEW YORK, 2002, 16 (08): : 1074 - +
  • [10] Clinical trials - Referral resource
    Trimble, E
    Valmonte, CM
    Cheson, BD
    ONCOLOGY-NEW YORK, 2000, 14 (06): : 850 - 850